<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">pembrolizumab based treatment <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">non active control</span> <span style="margin-left: 1em;">placebo <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2) progression or deaths (PFS) (2) objective responses (ORR) (2) DOR (2) DCR (1) AE leading to death (grade 5) (2) AE (any grade) (1) TRAE (any grade) (1) AE leading to treatment discontinuation (any grade) (1) TRAE (grade 3-4) (1) AE leading to treatment discontinuation (grade 3-4) (1) AE (grade 3-4) (1) TRAE leading to death (grade 5) (1) Abdominal pain TRAE (grade 3-4) (2) Adrenal insufficiency TRAE (grade 3-4) (1) Diabetes TRAE (grade 3-4) (1) Severe skin reaction TRAE (grade 3-4) (1) Myositis TRAE (grade 3-4) (1) Weight decreased TRAE (grade 3-4) (1) Peripheral oedema TRAE (grade 3-4) (1) Pruritus TRAE (grade 3-4) (1) Rash TRAE (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (1) Colitis TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Hepatitis TRAE (grade 3-4) (1) Dysgeusia TRAE (grade 3-4) (1) Stomatitis TRAE (grade 3-4) (1) Fatigue TRAE (grade 3-4) (1) Dyspepsia TRAE (grade 3-4) (1) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (1) Eczema TRAE (grade 3-4) (1) Infusion-related reactions TRAE (grade 3-4) (1) Hypothyroidism TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Thyroiditis TRAE (grade 3-4) (1) Pyrexia TRAE (grade 3-4) (1) Nausea TRAE (grade 3-4) (1) Arthralgia TRAE (grade 3-4) (1) Anaemia TRAE (grade 3-4) (1) Maculopapular rash TRAE (grade 3-4) (1) Decreased appetite TRAE (grade 3-4) (1) Asthenia TRAE (grade 3-4) (1) Dry skin TRAE (grade 3-4) (1) Dyspnoea TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Thrombocytopenia TRAE (grade 3-4) (1) Vomiting TRAE (grade 3-4) (1) Constipation TRAE (grade 3-4) (1) Leucopenia TRAE (grade 3-4) (1) Cough TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Myalgia TRAE (grade 3-4) (1) Headache TRAE (grade 3-4) (1) Hypophysitis TRAE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Abdominal pain AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Arthralgia AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Peripheral oedema AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 KEYNOTE-240, 2020 1 KEYNOTE-394, 2022 pembrolizumab alone vs. pembrolizumab based treatment
0.99 [0.71; 1.38] 0.99 [0.71;1.38]pembrolizumab alone vs. pembrolizumab based treatment
0.99 [0.71; 1.38] pembrolizumab alone vs. placebo
pembrolizumab alone better
0.78 [0.61; 1.00] 0.78 [0.61;1.00]pembrolizumab alone vs. placebo
pembrolizumab alone better
0.78 [0.61; 1.00] pembrolizumab based treatment vs. pembrolizumab alone
1.01 [0.72; 1.41] 1.01 [0.72;1.41]pembrolizumab based treatment vs. pembrolizumab alone
1.01 [0.72; 1.41] pembrolizumab based treatment vs. placebo
pembrolizumab based treatment better
0.79 [0.63; 0.99] 0.79 [0.63;0.99]pembrolizumab based treatment vs. placebo
pembrolizumab based treatment better
0.79 [0.63; 0.99] placebo vs. pembrolizumab alone
pembrolizumab alone better
1.28 [1.00; 1.64] 1.28 [1.00;1.64]placebo vs. pembrolizumab alone
pembrolizumab alone better
1.28 [1.00; 1.64] placebo vs. pembrolizumab based treatment
pembrolizumab based treatment better
1.27 [1.01; 1.59] 1.27 [1.01;1.59]placebo vs. pembrolizumab based treatment
pembrolizumab based treatment better
1.27 [1.01; 1.59] placebo pembrolizumab alone pembrolizumab based treatment direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C placebo pembrolizumab alone pembrolizumab based treatment placebo --- 1.28 1.00; 1.641.27 1.01; 1.59pembrolizumab alone 0.78 0.61; 1.00--- 0.99 0.71; 1.38pembrolizumab based treatment 0.79 0.63; 0.991.01 0.72; 1.41---
pathologies: 133
- treatments: 847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561
result logic